Key points are not available for this paper at this time.
This article describes the identification and management of depression due to bipolar disease. Data on the benefits and risks of the two therapies approved by the FDA, as well as those of nonapproved therapies, are reviewed.
Mark A. Frye (Wed,) studied this question.